Transcatheter Mitral Valve Implantation (TMVI) Using Edwards SAPIEN 3 Prostheses in Patients at Very High or Prohibitive Surgical Risk: A Single-Center Experience

Table 1

Patient demographics and comorbidities.

Patients treated (n = 7)
Female gender	86%
Age (years, mean, SD)	77 ± 8.1
Time since last mitral valve operation (month, mean, SD, n = 4)	161 ± 24
Number of thoracotomies per patient (median, IQR)	1 (1 to 1)
NYHA functional class prior to procedure
NYHA class IV	57% (4/7)
NYHA class III	43% (3/7)
NYHA class II	0% (0/7)
NYHA class I	0% (0/7)
Leading mitral valve dysfunction (native mitral valve, annuloplasty ring, or prosthesis)
Severe mitral valve regurgitation, ≥grade III	71% (5/7)
Severe mitral valve stenosis, ≥grade III	29% (2/7)
Prior aortic valve replacement
TAVR	0% (0/7)
SAVR	29% (2/7)
Bioprosthetic	14% (1/7)
Mechanical	14% (1/7)
Comorbidities
Chronic renal impairment (creatinine > 1.5 mg/dl)	57% (4/7)
Coronary artery disease	57% (4/7)
Prior CABG	43% (3/7)
Severe pulmonary hypertension (PAsys > 50 mmHg)	100% (7/7)
Atrial fibrillation	86% (6/7)
Prior stroke	29% (2/7)
Prior permanent pacemaker or ICD implantation	43% (3/7)
Chronic lung disease	71% (5/7)
Ejection fraction (mean)	51 ± 13%
Log. EuroSCORE I (mean)	39%